Sign In
Buy ENVB
$1.98
-0.240 (-10.81%)
At Close: Jun 03, 2026
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
08:00am, Wednesday, 25'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
08:00am, Thursday, 19'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
08:00am, Thursday, 29'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics t
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
05:00pm, Wednesday, 28'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08:00am, Wednesday, 28'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to
Enveric Biosciences Announces Patent Issuance
08:00am, Monday, 29'th Dec 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
04:46pm, Friday, 12'th Dec 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds
01:43pm, Thursday, 11'th Dec 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to
What Sparked Enveric Biosciences (ENVB) 74% Surge In After-Hours Trading?
10:31pm, Tuesday, 09'th Dec 2025
Enveric Biosciences shares soared 73.82% in after-hours trading after the company received a patent allowance for its EVM301 Series molecules.
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
08:00am, Tuesday, 09'th Dec 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
Enveric Biosciences (NASDAQ:ENVB) Shares Down 0.3% – Here’s What Happened
02:26am, Tuesday, 02'nd Dec 2025
Enveric Biosciences, Inc. (NASDAQ: ENVB - Get Free Report)'s stock price dropped 0.3% on Monday. The company traded as low as $5.62 and last traded at $5.72. Approximately 6,416 shares traded hands du
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
08:00am, Wednesday, 26'th Nov 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
04:05pm, Friday, 14'th Nov 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to addres
Enveric Biosciences Announces Reverse Stock Split
08:00am, Thursday, 23'rd Oct 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to addres
